Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracereoral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care

Huttner H, Gerner S, Kuramatsu J, Connolly SJ, Beyer-Westendorf J, Demchuk AM, Middeldorp S, Zotova E, Altevers J, Andersohn F, Christoph MJ, Yue P, Stross L, Schwab S (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 53

Pages Range: 532-543

Journal Issue: 2

DOI: 10.1161/STROKEAHA.121.034572

Abstract

BACKGROUND AND PURPOSE: It is unestablished whether andexanet alfa, compared with guideline-based usual care including prothrombin complex concentrates, is associated with reduced hematoma expansion (HE) and mortality in patients with factor-Xa inhibitor-related intracerebral hemorrhage (ICH). We compared the occurrence of HE and clinical outcomes in patients treated either with andexanet alfa or with usual care during the acute phase of factor-Xa inhibitor-related ICH.

Authors with CRIS profile

Involved external institutions

McMaster University Canada (CA) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) University of Calgary Canada (CA) Radboud University Nijmegen Netherlands (NL) Xcenda GmbH Germany (DE) Portola Pharmaceuticals United States (USA) (US)

How to cite

APA:

Huttner, H., Gerner, S., Kuramatsu, J., Connolly, S.J., Beyer-Westendorf, J., Demchuk, A.M.,... Schwab, S. (2022). Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracereoral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. Stroke, 53(2), 532-543. https://doi.org/10.1161/STROKEAHA.121.034572

MLA:

Huttner, Hagen, et al. "Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracereoral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care." Stroke 53.2 (2022): 532-543.

BibTeX: Download